微信公众号
证券之星APP
| 报告期 | 销售毛利率 | 同比 | 环比 | 行业排名 | 行业均值 | 行业龙头股 | 龙头股该指标值 | 查看 |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | 72.06% | 21.18% | 2.62% | 33/159 | 48.66% | 首药控股 | 96.95% | 行业排名> |
| 2026-03-31 | 70.22% | 24.3% | 10.84% | 33/159 | 50.28% | 海创药业 | 97.34% | 行业排名> |
| 2025-12-31 | 63.35% | -8.47% | -2.79% | 41/159 | 50.37% | 海创药业 | 99.82% | 行业排名> |
| 2025-09-30 | 65.17% | -4.04% | 9.58% | 40/159 | -2.12% | 海创药业 | 98.62% | 行业排名> |
| 2025-06-30 | 59.47% | -11.42% | 5.27% | 54/159 | 15.05% | 海创药业 | 99.57% | 行业排名> |
| 2025-03-31 | 56.49% | -14.41% | -18.38% | 59/159 | 31.79% | 海创药业 | 99.52% | 行业排名> |
| 2024-12-31 | 69.21% | -14.81% | 1.92% | 34/159 | 51.61% | 艾力斯 | 96.74% | 行业排名> |
| 2024-09-30 | 67.91% | -15.22% | 1.15% | 35/159 | 22.43% | 首药控股 | 98.96% | 行业排名> |
| 2024-06-30 | 67.13% | -14.17% | 1.71% | 36/159 | 32.96% | 迪哲医药 | 97.73% | 行业排名> |
| 2024-03-31 | 66% | -22.8% | -18.77% | 35/159 | 51.47% | 百利天恒 | 97.99% | 行业排名> |
| 2023-12-31 | 81.25% | -4.24% | 1.44% | 21/159 | 51.31% | 百利天恒 | 98.92% | 行业排名> |
| 2023-09-30 | 80.09% | -5.93% | 2.4% | 25/159 | 32.31% | 迈威生物 | 98.93% | 行业排名> |
| 2023-06-30 | 78.22% | -8.2% | -8.51% | 25/159 | 38.22% | 迈威生物 | 99.59% | 行业排名> |
| 2023-03-31 | 85.49% | -1.02% | 0.76% | 14/159 | 52.66% | 迈威生物 | 99.8% | 行业排名> |
| 2022-12-31 | 84.85% | -0.42% | -0.35% | 15/159 | 53.51% | 迈威生物 | 99.46% | 行业排名> |
| 2022-09-30 | 85.14% | -1.21% | -0.07% | 12/159 | 5.67% | 迈威生物 | 99.75% | 行业排名> |
| 2022-06-30 | 85.2% | 0.6% | -1.35% | 12/159 | 20.91% | 迈威生物 | 99.67% | 行业排名> |
| 2022-03-31 | 86.37% | 1.6% | 1.37% | 12/159 | 54.06% | 迈威生物 | 99.44% | 行业排名> |
| 2021-12-31 | 85.21% | -0.88% | -1.14% | 19/159 | 54.9% | 迈威生物 | 98.57% | 行业排名> |
| 2021-09-30 | 86.18% | -0.08% | 1.76% | 14/159 | 46.49% | 首药控股 | 99.93% | 行业排名> |
| 2021-06-30 | 84.69% | 4.05% | -0.37% | 15/159 | 46.97% | 艾力斯 | 99.41% | 行业排名> |
| 2021-03-31 | 85.01% | 3.6% | -1.11% | 14/159 | 53.79% | 艾力斯 | 98.7% | 行业排名> |
| 2020-12-31 | 85.97% | 1.97% | -0.34% | 13/159 | -147.51% | 艾力斯 | 99.4% | 行业排名> |
| 2020-09-30 | 86.26% | 2% | 5.97% | 11/159 | 56.06% | 首药控股 | 99.94% | 行业排名> |
| 2020-06-30 | 81.39% | -1.86% | -0.81% | 15/159 | 53.85% | 泽璟制药 | 99.96% | 行业排名> |
| 2020-03-31 | 82.06% | 2% | -2.67% | 13/159 | 54.83% | 微芯生物 | 95.14% | 行业排名> |
| 2019-12-31 | 84.3% | 3.82% | 1.65% | 12/159 | -1232.76% | 多瑞医药 | 95.59% | 行业排名> |
| 2019-06-30 | 82.93% | 2% | 2.13% | 13/159 | 54.88% | 微芯生物 | 95.81% | 行业排名> |
| 2018-12-31 | 81.2% | 2.67% | 2.67% | 19/159 | -210.26% | 微芯生物 | 96.09% | 行业排名> |
| 2017-12-31 | 79.09% | 0.48% | 0.48% | 16/159 | 52.25% | 微芯生物 | 96.11% | 行业排名> |
| 2016-12-31 | 78.71% | 2% | 2% | 12/159 | 48.17% | 微芯生物 | 95.5% | 行业排名> |